Nuvectis Pharma, Inc. (NVCT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$17.76-3.84%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · NVCT
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | |||||||
| R&D Expenses | 41.2 | 18.2 | 12.9 | 15.4 | 13.2 | 9.5 | — |
| Operating Income | (52.1) | (27.6) | (19.8) | (22.9) | (19.2) | (12.9) | — |
| Net Income | |||||||
| Net Income | (50.5) | (26.4) | (19.0) | (22.3) | (19.1) | (12.9) | — |
| Per Share | |||||||
| Basic EPS | (1.71) | (1.32) | (1.11) | (1.43) | (1.51) | (3.02) | — |
| Diluted EPS | (1.71) | (1.32) | (1.11) | (1.43) | (1.51) | (3.02) | — |
| Dividend per Share | — | — | — | 0.00 | 0.00 | — | — |
| Basic Weighted Avg Shares | 29.5 | 21.8 | 17.1 | 15.6 | 12.7 | 4.3 | — |
| Diluted Weighted Avg Shares | 29.5 | 21.8 | 17.1 | 15.6 | 12.7 | 4.3 | — |
| Supplemental | |||||||
| EBIT | (52.1) | (27.6) | (19.8) | (22.9) | (19.2) | (12.9) | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.